ImmunityBio Inc
Research ImmunityBio Inc (IBRX) on Bullrun: market cap USD 8.58B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerIBRX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 8.58B
- Financial periodQ2 2026
- RevenueUSD 51.24M
- Net income-USD 230.38M
- Free cash flow-USD 70.03M
- Gross margin99.4%
Valuation Snapshot
latest market cap is USD 8.58B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 113.29M | -USD 351.50M | -USD 308.78M | 99.3% | -0.38 | USD 88.33M | USD 1.75M | -USD 500.47M |
| FY2024 | USD 14.75M | -USD 413.60M | -USD 398.12M | 100.0% | -0.62 | USD 143.43M | USD 1.25M | -USD 489.10M |
| FY2023 | USD 622.00K | -USD 583.90M | -USD 397.34M | 100.0% | -1.15 | USD 265.45M | USD 726.72M | -USD 586.99M |
| FY2022 | USD 240.00K | -USD 417.30M | -USD 415.67M | 100.0% | -1.04 | USD 104.64M | USD 664.68M | -USD 447.33M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 8.58B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 2.00B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 2.18B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 3.37B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 2.13B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 2.42B | n/a | n/a | n/a |
About ImmunityBio Inc
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is ImmunityBio Inc's market cap?
ImmunityBio Inc's market capitalization is USD 8.58B.
What does ImmunityBio Inc do?
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors.